A peptide corresponding to the sequence 169-193 of the second extracellular loop of the human muscarinic acetylcholine receptor-2 was used as an antigen to screen sera from patients with idiopathic dilated cardiomyopathy (DCM, n = 36) and healthy blood donors (HBD, n = 40). The sera from 14 patients with DCM (38.8%) and 3 HBD (7.5%) recognized the muscarinic receptor peptide at dilutions varying from 1:20 to 1:160 in ELISA. A highly significant correlation (P = 0.006) was found between the presence of antimuscarinic receptor-2 autoantibodies and anti-fl-adrenoceptor-1 autoantibodies in the patients' sera. Affinity-purified autoantibodies from positive sera of patients with DCM recognized on the electrotransferred protein of rat ventricular membrane a major band of about 80 kD. Incubation of autoantibodies with membrane resulted not only in a decrease in the maximal binding sites (B..) but also in an increase in Kd of radioligand binding in a concentration-dependent manner. This suggests a mixed-type of inhibition. Moreover, preincubation with atropine abolished the inhibitory effect of autoantibodies on the receptor binding whereas carbachol appeared to have no effect on the activity of the autoantibodies.
Introduction
There is increasing evidence for the participation of cellular and humoral autoimmunity in the pathogenesis of human idiopathic dilated cardiomyopathy (DCM)' (1) (2) (3) (4) . Autoim-munity is now being regarded as one ofthe important etiological mechanisms (5) (6) (7) . Recently, autoantibodies against cardiac ,B-adrenoceptors have been characterized in patients with DCM in our laboratory (8) and have been found in 36% ofthe patients. Other myocardial cell surface receptors and ion channels might also be involved in autoimmune recognition leading to cardiac dysfunction. Therefore, our attention was focused on the muscarinic cholinergic receptor, another seven-transmembrane region and G-protein-regulated receptor which, together with the f.-adrenoceptor, coordinately modulates the activity of myocardial adenylyl cyclase and ion channels, and thus regulates cardiac function.
The primary sequence ofthe human muscarinic receptor-2 was derived from the corresponding DNA sequence (9, 10) .
The second extracellular loop of the f-adrenoceptors was proposed as a possible target for autoimmune attack in view of its immunological and functional properties (8) . Since all receptors ofthe rhodopsin family share structural features, a peptide was synthesized corresponding to the sequence of this loop in the cardiac muscarinic cholinergic receptor. This peptide was used both to detect autoantibodies by an enzyme immunoassay and to purify them by affinity-chromatography for further characterization.
Methods
Patient recruitment and evaluation. Patients with idiopathic DCM (n = 36) were selected from those admitted to the Division ofCardiology, Sahlgren's Hospital, Goteborg (Sweden). All patients had echocardiographic findings consistent with dilated cardiomyopathy and left ventricular dysfunction with an ejection fraction below 45% in M mode tracing. The clinical characteristics are summarized in Table I . Patients with hypertrophic cardiomyopathy, ischemic heart disease, hypertension, valvular heart disease, diabetes, and other infections were excluded from this study. The patients with DCM in this study are entirely different from those previously studied (8) .
Sera from healthy blood donors (HBD) (n = 40) were obtained from the blood bank of the hospital and served as the control group.
Peptides. A peptide corresponding to the sequence (residues ) of the second extracellular loop of the human muscarinic receptor-2 with a cystein as carboxy terminus: human ,B-adrenoceptor-1 (8) was also used to screen sera from the same subjects to study the possible correlation between autoantibodies against both muscarinic-and #-adrenergic receptors.
Antibody purification. The synthetic peptide was used as an antigen to immunize two rabbits. 1 mg of free peptide was emulsified in com- Immunoblotting assay. Rat cardiac membrane was used as the source of muscarinic receptor-2 for immunoblotting and radioligand binding since heterologous systems have been previously used to demonstrate antireceptor antibodies in human disease (7, (12) (13) (14) . Moreover, the peptide we used corresponds to a sequence totally conserved in both humans and rats ( 15) . Membrane proteins (75 Mg), prepared from normal rat ventricles as described ( 16) , were subjected to electrophoresis on a 10% polyacrylamide gel in SDS and thereafter subjected to electrotransfer to nitrocellulose that was saturated with PMT buffer for 2 h at room temperature. The affinity-purified antibodies from patients and rabbits, and the mouse monoclonal antibody (mAb-35) ( 17) against calf brain muscarinic receptor used as a positive control, were incubated at 4°C overnight with the nitrocellulose strips. After the strips were washed in PMT, they were incubated with a 1:500 dilution of affinity-purified biotinylated rabbit anti-human IgG (for human autoantibody), donkey anti-rabbit IgG (for rabbit antibody), and rabbit anti-mouse IgG (H + L) (for monoclonal antibody), for 1 h at room temperature followed by incubation with 1:500 streptavidin peroxidase solution in the same buffer. Strips were washed in PMT and in PBS containing 0.1% Triton X-100 before adding the chromogenic substrate H202-4-chloro-1 -naphthol. As soon as the protein bands were revealed, strips were washed extensively in water and stored at -200C.
Profiles ofimmunoblots were then compared with both rabbit polyclonal and mouse monoclonal antibodies. The specificity was checked by a blocking effect of the corresponding peptide after preincubation with autoantibody overnight at 4VC.
Binding characteristics of muscarinic receptors. Muscarinic receptors were determined by use of [3H] QNB (New England Nuclear, Boston, MA). Binding assays were carried out in abuffer(pH 7.4): 50mM sodium/potassium phosphate buffer containing 10 mM MgC12, except where otherwise stated. Saturation-binding isotherms were obtained by incubating membranes for 1 h with varying concentrations ofquinuclidinyl benzilate (QNB) (0.125 nM-4 nM) at 260C. Specific binding was defined as that displaced by 2 AM (-) atropine. The reaction was terminated by dilution with 5 ml ice-cold buffer. The samples were then poured over GF/B 2.5 cm glass microfiber filters (Whatman International Ltd., Maidstone, England) under reduced pressure followed by a wash with 10 ml ofbuffer. Filters were counted in a liquid scintillation counter (LKB Instruments, Inc., Bromma, Sweden). The density of muscarinic receptor (B.) and the dissociation constant (Kd) were determined by nonlinear least-squared fitting (18) .
The activity of autoantibody was observed after preincubation of autoantibody with membrane for 30 min at 370C with shaking, before binding studies were performed. To study the protective effects of muscarinic ligands on the autoantibody activity, membranes were preincubated with 100 nM atropine or 10MM carbachol for 2 hat 4VC. Autoantibodies were then added to a final concentration of 200 nM and incubated 30 min at 370C. The membranes were then diluted four times in order to minimize the effects of the agonist and the antagonist on QNB binding characteristics. Statistics. Statistics were calculated using the Statview SE+Graph-icsTM vs. 1 .03 software on a Macintosh personal computer. P < 0.05 was considered to be statistically significant.
Results
Detection of autoantibodies by ELISA. Positivity was defined as 2.5 times the background optical density. 14 sera from patients with DCM (38.8%) and 3 sera from HBD (7.5%) recognized the muscarinic receptor-2 peptide at dilutions varying from 1:20 to 1:160 (Fig. 1) . No difference in titers was observed between the positive sera of the healthy controls and that of the patients. The difference between the control group and patients with DCM was significant at the 95% level as determined by an ANOVA analysis (Statview the New York Heart Association (NYHA) functional class of the studied patients.
The possible correlation between autoantibodies of muscannic receptor-2 and autoantibodies of 4-1 adrenoceptor was also studied in the above sera (Table II) . Sera from 13 patients with DCM (36.1%) and 6 sera from HBD (15%) recognized the #4-1 adrenoceptor peptide, confirming our previous study (8) , as the population of patients with DCM in the present study is entirely different from those previously studied. A highly significant correlation (P = 0.006) was found between the presence of antimuscarinic receptor-2 autoantibodies and anti-:-1 adrenoceptor autoantibodies.
Monospecificity of autoantibodies by immunoblotting. In order to ascertain that the affinity-purified autoantibodies were able to recognize the receptor protein, immunoblots were performed on membranes prepared from normal rat ventricles. Autoantibodies recognized, on the electrotransferred protein of rat cardiac membrane, a major protein band with a molecular weight ofabout 80 kD, showing the same mobility as the [3H]-PrBCM-labeled band ( 10). This band was monospecific for the muscarinic receptor-2 since its staining was blocked after preincubation with the muscarinic receptor-2 peptide and it coincided well with the band revealed by both rabbit antipeptide polyclonal antibodies and the main band revealed by the monoclonal antimuscarinic receptor antibody (Fig. 2) . These results confirmed that the autoantibody could recognize the muscarinic receptor-2 protein in a specific manner.
Functional effect ofautoantibodies on ligand binding to the muscarinic receptors. The affinity-purified autoantibodies induced a decrease in Bm. and an increase in Kd ofQNB binding on rat myocardial membranes. Antibodies affinity purified from HBD were devoid of these effects (Fig. 3) . Moreover, preincubation of the autoantibodies with the corresponding peptide totally abolished the effect described.
The effect of autoantibodies was dose dependent, reaching a maximal decrease in B.,,, of approximately 50% and a maximal increase in Kd of approximately five times the control value (Table III) .
Effect ofthe coupled state ofthe muscarinic receptor on the activity ofautoantibody. By using Gpp(NH)p, it is possible to completely uncouple the receptor from the G-protein, e.g., Gi or Go. Membranes incubated in the presence or absence of Gpp(NH)p ( 100 ,uM) showed a similar change in Bm. and Kd upon incubation with the autoantibodies (Table IV) .
Effect ofmuscarinic agonist and antagonist on the activity ofthe autoantibodies. Preincubations with the muscarinic receptor non-subtype-specific antagonist, atropine, and the non- subtype-specific agonist, carbachol, were performed on the muscarinic receptors ofthe rat ventricular membrane to assess their effects on the activity ofautoantibodies. Atropine blocked the effect of the autoantibodies on QNB binding to the muscarinic receptor, whereas carbachol appeared to have no effect (Fig. 4) ited value since the identification of the specific functional autoantibody population is not possible. The findings reported in this study represent, to our knowledge, the first demonstration of the presence of antimuscarinic receptor-2 autoantibodies in DCM. Based on the putative structure of the human muscarinic receptor-2, we predicted a sequence that might be involved in an autoimmune recognition of this receptor. Three criteria were used to select this sequence. First, the sequence located at the second extracellular loop of the receptor should be accessible for autoimmune attack. Second, the length of this sequence should be compatible with the presence of T-and B-cell epitopes and could thus be immunogenic as well as antigenic. Third, it has been shown by site-directed mutagenesis that, as in the f3-adrenoceptors, the cysteine residue located in this loop of the muscarinic-1 receptor is essential for ligand binding (20) . The effective immunogenicity ofthe selected sequence was confirmed by raising antibodies against the corresponding free peptide in rabbits (Fig. 2 ).
An overlap between the presence ofautoantibodies directed against the second extracellular loop of the muscarinic receptor-2 and autoantibodies against the second extracellular 3-1 adrenoceptor was found. 57% ofthe patients with autoantibodies against muscarinic receptor-2 also had autoantibodies against 03-adrenergic receptors. The highly significant correlation between the presence of antimuscarinic receptor-2 and anti-,B-1 adrenoceptor autoantibodies suggests the multiplicity of the autoimmune response in DCM. This is in accordance with the different autoantigens that have already been described in patients with dilated cardiomyopathy (4) and in mice susceptible to Coxsackievirus B3-induced myocarditis (21, 22) . These observations make it unlikely that molecular mimicry (23) is the etiological trigger of the autoimmune response. It is more likely that cell injury as occurs with viral infection leads to release of autoantigens which, in the context of atopical expression of HLA II antigen, could initiate an autoimmune process (24) . Alternatively, a first autoimmune triggering by autoantibodies cross-reacting between a pathogen and one of the heart receptors could lead to cell damage and a polymorphic autoimmune response. The purified antimuscarinic receptor antibody of the patients recognized the muscarinic receptor-2 protein. This was demonstrated by comparative immunoblots using as controls a mouse monoclonal antibody against the calf brain muscarinic receptor (mAb-35) (17) and rabbit antipeptide polyclonal antibodies. These results suggested that peptide recognition as tested in the enzyme immunoassay reflects recognition of the muscarinic receptor-2 protein.
Ligand binding studies ofthe affinity-purified autoantibodies of the patients showed the ability in vitro not only to decrease the maximal binding sites but also to decrease antagonist affinity. This implies a mixed type of inhibition (25) in which the antibody does not bind at the same site of the radioligand but, by binding, decreases the affinity for the radioligand binding site. Affinity-purified autoantibodies from a healthy control group had no effect, suggesting that these autoantibodies from control sera are directed against nonfunctional epitopes on the peptide.
Using the experimental approach in which coupling to the effector molecules is believed to be blocked in the presence of GppNHp, no significant change in the antibody activity was found. Thus, the recognition of autoantibody by muscarinic receptors is not influenced by its coupling state. This result is compatible with that found in the autoimmune response against the (3-1 adrenoceptor (26) .
The effects of the muscarinic receptor agonist, carbachol, and the antagonist, atropine, upon the inhibition ofmuscarinic radioligand binding by the autoantibodies were of particular interest. The agonist carbachol did not inhibit the effect on the maximal binding sites ofthe autoantibodies, whereas the antagonist atropine was able to protect the receptor from this effect. These findings are in marked contrast with the effects of (3-adrenergic ligands on the activity of antireceptor antibodies studied before (26) . Indeed, the antagonist metoprolol did not protect the (3-1 adrenergic receptor from deactivation by antireceptor antibodies, while the agonist isoproterenol deactivated the receptor in the same way as the antibodies (26) .
The efficiency of atropine and the inefficiency of carbachol to protect the receptor from the pharmacological effects of the autoantibodies could be explained by the fact that in the antagonist-receptor complex the functional epitope is "cryptic" while it is accessible on the free receptor or on the agonist-receptor complex. Recent studies using rabbit anti-peptide antibodies sharing the pharmacological properties ofthe human autoantibodies showed that the former could inhibit isoproterenol-stimulated adenylyl cyclase activity (Fu, L-X., G. Wallukat, A. Hjalmarson, and J. Hoebeke, manuscript submitted for publication). This suggests that the autoantibodies could have an "agonist-like" effect on the muscarinic receptor. The concentration ofautoantibodies in serum calculated from the amount purified was estimated at 200 nM. The in vivo concentration could thus have a pharmacological effect on the receptor in patients who only have anti-muscarinic receptor autoantibodies. Since the concentration needed to pharmacologically affect the --1 adrenoceptor is 10 times lower ( 8 ) than that needed to affect the muscarinic receptor, it is very difficult to deduce the overall effect on heart function ofthe simultaneous presence of both antireceptor autoantibodies. More studies are needed to resolve how such receptor antibodies could interfere with the delicate balance between sympathetic and vagal stimulation of the heart function and thus contribute to the overall symptomatology of DCM.
In conclusion, by using a synthetic peptide we have been able to identify a subgroup of patients with idiopathic DCM who had in their sera functionally active antimuscarinic receptor-2 autoantibodies. These autoantibodies were directed against the putative second extracellular loop of the receptor. We have previously shown that the corresponding loop of the fl-adrenergic receptor is the target of an autoimmune response against the j-I adrenergic receptor in patients with DCM (8) and against the (3-2 adrenergic receptor in patients with myasthenia gravis (27) and in patients with Chagas' disease (unpublished observations). These results strongly suggest that the second extracellular loop of G-protein-coupled receptors could contain a region similar to the MIR (main immunogenic region) as was shown for the nicotinic acetylcholine receptor (28) .
